Cargando…

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

BACKGROUND: Cabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary objectives were to report dose-limiting toxicities (DLTs) and to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, Campone, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854123/ https://www.ncbi.nlm.nih.gov/pubmed/24099585 http://dx.doi.org/10.1186/1471-2407-13-460

Ejemplares similares

Preclinical profile of cabazitaxel
por: Vrignaud, Patricia, et al.
Publicado: (2014)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
por: Diéras, Véronique, et al.
Publicado: (2016)

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
por: Rixe, Olivier, et al.
Publicado: (2015)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer
por: Martin, Nicolas, et al.
Publicado: (2018)

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
por: Wachters, F M, et al.
Publicado: (2004)

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors
por: Isambert, Nicolas, et al.
Publicado: (2013)

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
por: Chen, X, et al.
Publicado: (2003)

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
por: Le Tourneau, C., et al.
Publicado: (2022)

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
por: Rasschaert, M, et al.
Publicado: (2007)

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
por: Sarantopoulos, John, et al.
Publicado: (2017)

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series
por: Malalagama, Geethal N., et al.
Publicado: (2017)

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
por: Diaz-Padilla, I, et al.
Publicado: (2012)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
por: Janssen, A, et al.
Publicado: (2017)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study
por: Chanteloup, Gaétan, et al.
Publicado: (2020)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients
por: Terada, Naoki, et al.
Publicado: (2019)

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer()()
por: Bahl, Amit, et al.
Publicado: (2022)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
por: Michaelson, M D, et al.
Publicado: (2013)

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
por: Evans, T. R. Jeffry, et al.
Publicado: (2019)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects
por: Kommineni, Nagavendra, et al.
Publicado: (2019)

Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer
por: Nlandu, Yannick, et al.
Publicado: (2019)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Development of a Plasmonic Sensor for a Chemotherapeutic Agent Cabazitaxel
por: Aşır, Süleyman, et al.
Publicado: (2022)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Cabazitaxel-Induced Stabilization of Microtubules Enhances Radiosensitivity in Ovarian Cancer Cells
por: Kunos, Charles A., et al.
Publicado: (2013)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Reduction-Responsive Stearyl Alcohol-Cabazitaxel Prodrug Nanoassemblies for Cancer Chemotherapy
por: Liu, Yuting, et al.
Publicado: (2023)

Topical Drug Delivery of Concentrated Cabazitaxel in an α‐Tocopherol and DMSO Solution
por: Sun, Boyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_umvinu8m8ic3gmg0ps7lskk7n3